Polaryx Therapeutics, Inc. (PLYX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US73110F1003
Polaryx Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -7.82 m USD |
| EBIT | -8.99 m USD |
| Net income | -8.99 m USD |
| Diluted EPS – continuing operations | -0.20 USD |
Full history since 2023, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
More stocks
- Sagittarius Life Science (3205.TWO)
- We&Win Diversification Co Ltd (4113.TWO)
- MSC Co. Ltd (009780.KQ)
- Leo Systems (5410.TWO)
- QDM International Inc. (QDMI)
- DATA MODUL Aktiengesellschaft Produktion und Vertrieb von elektronischen Systemen (DAM.DE)
- Webjet Group Ltd (WJL.AX)
- First Northwest Bancorp (FNWB)
- Unitron Tech Co Ltd (142210.KQ)
- Madup Inc. (0039P0.KQ)
- Ablerex Electronics Co Ltd (3628.TWO)
- Lotte Himart (071840.KS)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.